Vesalio

Executive Summary

Vesalio is a privately held medical device company headquartered in Nashville, Tennessee, founded in 2015. The company is dedicated to advancing the treatment of vascular occlusions by developing innovative thrombectomy devices for neurovascular, cardiovascular, and peripheral vascular applications. Its mission is to improve clinical outcomes for patients suffering from conditions such as acute ischemic stroke, pulmonary embolism, and peripheral artery disease. By focusing on next-generation catheter-based technologies, Vesalio aims to address limitations of current mechanical thrombectomy approaches, including clot retrieval efficacy and procedural safety. The company's portfolio targets large and growing markets driven by aging populations and increasing prevalence of vascular diseases. As a private entity with limited public disclosures, Vesalio is likely in the later stages of product development or early commercialization. The thrombectomy landscape is competitive, with established players like Medtronic and Stryker, but Vesalio's differentiated technology could capture share if clinical data demonstrate superior outcomes. Key near-term catalysts include FDA clearances for expanded indications, publication of clinical trial results, and strategic partnerships for distribution or co-development. While the company's valuation and funding history are undisclosed, its focus on high-growth vascular segments and innovative device design positions it as a potential acquisition target or IPO candidate in the coming years.

Upcoming Catalysts (preview)

• Q1 2026FDA 510(k) clearance for next-generation neurovascular thrombectomy device70% success
• Q2 2026Publication of pivotal trial results for peripheral vascular thrombectomy system60% success
• Q3 2026Strategic distribution partnership with a major cardiovascular hospital network50% success